News

The ALN-VSP Phase I trial is designed to recruit patients with advanced solid tumors with liver involvement who have failed to respond to or have progressed after standard

Daxas (roflumilast) is an orally administered selective phosphodiesterase 4 (PDE4) enzyme inhibitor, which has been shown to inhibit COPD related inflammation with a novel mode of action. The

Livatag is a treatment presented in nanoparticles able to deliver doxorubicin in chemoresistant cells. It was granted an orphan drug status in Europe and in the US. The

Each retail package of Sucanon contains 60 tablets and is the equivalent of a one-month patient supply. Pre-clinical and clinical studies of Sucanon showed that Sucanon and other

PRT062607 is a novel, oral Spleen Tyrosine Kinase (Syk)-specific kinase inhibitor in development to treat chronic inflammatory diseases, including rheumatoid arthritis and systemic lupus erythematosis, and certain cancers,

FDA alleged in letters to drug companies that their products were ‘unapproved new drugs’ which can no longer be marketed legally in the US for safety problems associated

With this acquisition, Laboratoires Thea is planning to strengthen its geographical presence by establishing new affiliates in countries where the company’s products were either sold through distributors or

GBR401 has been developed completely in-house by Glenmark‘s Biologics Research Centre located in Switzerland, using an advanced technology. GBR 401 targets lymphomas, leukemia’s of B-cell origin and inflammatory

to-BBB is planning to initiate the Phase I/II clinical trial in a few months at three academic hospitals in the Netherlands led by neuro-oncology experts of the Antoni